- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -
- Dr. Prabir Roy-Chaudhury is the Immediate Past President of the American Society of Nephrology, serves as the Drs Ronald and Katherine Falk Eminent Professor at UNC, and is the Co-Director of the UNC Kidney Center -
DURHAM, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Robert J. (Rob) Kossmann, MD, FACP, FASN and Prabir Roy-Chaudhury, MD, PhD, FASN, have joined the Company as advisors to prepare for Humacyte's planned commercialization of the acellular tissue engineered vessel (ATEV) in hemodialysis access. In their roles, these leading nephrologists will contribute to the development of health economic, reimbursement and market access strategies as well as provide peer-to-peer scientific support and medical education. These appointments follow the release last month of positive results from the V012 Phase 3 dialysis access study in women and Humacyte's announcement of plans to file a supplemental Biologic License Application with the Food and Drug Administration.
Dr. Kossmann is a leading nephrologist and healthcare executive who served in senior medical leadership roles at Fresenius Medical Care from 2014 - 2026, including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America. Prior to joining Fresenius, he practiced clinical nephrology for more than two decades and developed extensive expertise in chronic kidney disease, dialysis, and multi-organ disease management. Dr. Kossmann earned his Doctor of Medicine degree from Case Western Reserve University and completed his nephrology training at the University of Washington. Throughout his career, he has been a prominent advocate for kidney disease patients and the nephrology profession, serving as President of the Renal Physicians Association, participated in founding the organization's Nephrology Coverage Advocacy Program, advising the American Medical Association on nephrology reimbursement issues, and helping establish the New Mexico Renal Disease Collaborative Group.
Dr. Roy-Chaudhury is an internationally recognized nephrologist, researcher, and academic leader who serves as the Drs. Ronald and Katherine Falk Eminent Professor of Nephrology and Co-Director of the UNC Kidney Center at the University of North Carolina at Chapel Hill, as well as a staff nephrologist at the Salisbury VA Medical Center. A graduate of the Armed Forces Medical College in Pune, India, he completed training in internal medicine and nephrology at the University of Aberdeen in Scotland and Beth Israel Hospital at Harvard Medical School. His research focuses on uremic vascular biology, dialysis vascular access, and cardiovascular complications in kidney disease, and he has received extensive NIH, VA, and industry funding. Dr. Roy-Chaudhury has published more than 250 scientific manuscripts and book chapters, delivered hundreds of lectures worldwide, and held numerous leadership positions within the nephrology community, including as President of the American Society of Nephrology (ASN) for 2025. He was also the founding ASN co-chair of the Kidney Health Initiative, a public-private partnership between the ASN and the U.S. Food and Drug Administration aimed at accelerating innovation in kidney disease treatments and technologies.